Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Guided Therapeutics (GTHP) over the last 15 years, with Q3 2025 value amounting to -$277000.0.

  • Guided Therapeutics' Free Cash Flow rose 4143.76% to -$277000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 million, marking a year-over-year increase of 124.67%. This contributed to the annual value of -$1.1 million for FY2024, which is 3591.07% up from last year.
  • Guided Therapeutics' Free Cash Flow amounted to -$277000.0 in Q3 2025, which was up 4143.76% from -$169000.0 recorded in Q2 2025.
  • In the past 5 years, Guided Therapeutics' Free Cash Flow ranged from a high of $155000.0 in Q4 2021 and a low of -$744000.0 during Q3 2021
  • Over the past 5 years, Guided Therapeutics' median Free Cash Flow value was -$336000.0 (recorded in 2023), while the average stood at -$355684.2.
  • Per our database at Business Quant, Guided Therapeutics' Free Cash Flow skyrocketed by 14682.78% in 2021 and then crashed by 32064.52% in 2022.
  • Guided Therapeutics' Free Cash Flow (Quarter) stood at $155000.0 in 2021, then crashed by 320.65% to -$342000.0 in 2022, then grew by 1.75% to -$336000.0 in 2023, then grew by 1.19% to -$332000.0 in 2024, then grew by 16.57% to -$277000.0 in 2025.
  • Its last three reported values are -$277000.0 in Q3 2025, -$169000.0 for Q2 2025, and -$331000.0 during Q1 2025.